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milk fat globule (HMFG) and a hybridoma that produces 
1 1D10. The hybridoma that produces 1 1D10 Was selected by 
speci?c procedures. 11D10 induces an immunological 
response to HMFG in mice, rabbits, monkeys and patients 
With advanced HMFG-associated tumors. This invention pro 
vides compositions derived from polynucleotide sequences 
encoding the variable light and/ or variable heavy regions of 
monoclonal anti-idiotype antibody 11D10, as Well as 
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of HMFGiassociated tumors. 
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Figure 3A 
DIQMTQSPSSLSASLGQRV SLTC — Framework #1, 1-23 
RASQDIGINLH — CDR~1, 24-34 
TLQQEPDGTIKRLIY — Framework #2, 35-49 
ATSSLGS — CDR-Z, 50-56 
GVPKRFSGSRSGSDYSLTISSLESGDFVAYYC -— Framework #3, 57-88 
LQYASSPYT -— CDR-3, 89—97 
F GGGTKLEIK —- Framework #4, 98-107 
US. Patent Jul. 15, 2008 Sheet 4 0f 34 US 7,399,849 B2 
Figure 3B 
QAYLQQSGAELVRSGASVKMSCKASGYTLT -- Framework #1, 1-30 
SYNMH — CDR-l, 31-35 
WVKQTPGQGLEWIG —— Framework #2, 36-49 
NIFPGNGDTYYNQKFKG — CDR-Z, 50-66 
KASLTADTSSSTAYMQISSLTSEDSAVYFCAR —— Framework #3, 67-98 
GNWEGALDY — CDR-3, 99-107 
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